Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

MSTX RSS Feed
Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rhodey Red
Search This Board:
Last Post: 12/18/2014 1:46:31 PM - Followers: 306 - Board type: Free - Posts Today: 0

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.


http://wsw.com/webcast/cowen16/MSTX/  Webcast from Cowen Healthcare Conference 03/03/14

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_07.09.2013.pdf


http://www.media-server.com/m/p/to9vgb8uhttp://www.media-server.com/m/p/to9vgb8u  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_10.08.2013.pdf    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW

http://www.masttherapeutics.com/company/ceo-blog/ 
Blog Update from CEO B. Culley 12/12/13  NEW

http://www.masttherapeutics.com/investors/news/?releaseid=1887966  Data From Proof of Concept Study in Heart Failure 
01/06/13


ClinicalTrials.gov

 
A service of the U.S. National Institutes of Health

 

  • Make bi

 

Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Sponsor:
Mast Therapeutics, Inc.
Information provided by (Responsible Party):
Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01737814
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.


Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3
 
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Resource links provided by NLM:
 
Further study details as provided by Mast Therapeutics, Inc.:
 
Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]
    Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]
 
Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline

 

 
Please refer to this study by its ClinicalTrials.gov identifier: NCT01737814

Contacts
Contact: Mast Therapeutics CT.gov Call Center 1-888-965-1238  

 
Responsible Party: Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on July 25, 2013

 

Technology

 

Hematology

MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.


Oncology

Exelbine™

Exelbine™, or ANX-530 (vinorelbine injectable emulsion), is a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®). We are seeking a partner or outside investor to continue development of the Exelbine program.

ANX-514

ANX-514 (docetaxel for injectable emulsion) is a novel, detergent-free emulsion formulation of the chemotherapy drug docetaxel. We are seeking a partner or outside investor to continue development of the ANX-514 program.



2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing


Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule

Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14  Application Submitted

Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated

Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14 Positive Top line Data released 9/8/14

Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14

Receive protocol from FDA for Phase 2 Heart Failure Study Q4'14 FDA Approves Heart Failure Study 12/9/14




 

Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug 
http://www.youtube.com/watch?v=eI7inPOiyZM&feature=youtu.be 
http://www.masttherapeutics.com/wp-content/uploads/2013/04/EPIC-An-Ongoing-Pivotal-Phase-3-Study-in-Patients-with-Sickle-Cell-Disease-Aug-21-2013.pdf

http://whalewisdom.com/stock/mstx

http://whalewisdom.com/schedule13d/view/90323

http://whalewisdom.com/schedule13d/view/103504

http://whalewisdom.com/schedule13d/view/90288

http://whalewisdom.com/filer/stock_history/ancora-advisors-llc/mstx/
 

Schedule 13D and 13G filings submitted since 03/31/2013

  Filing Company Date of
Filing
Total Reported
Shares Owned
Shares Reported
on 13F
  Baker Bros LLC 03/31/14 3,000,000 3,000,000
SC 13G SABBY MANAGEMENT, LLC 11/07/2014 8,854,300 8,854,300
SC 13G FRANKLIN RESOURCES INC 07/10/2013 10,987,000 12,000,000
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F MPM Asset Management     MSTX 2,551,851    
13F Vanguard Group     MSTX 2,810,791    
 



 

                                                                       






http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=2&g=0&id=p32395513381

http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=9&g=0&id=p36778398928

http://stockcharts.com/freecharts/gallery.html?MSTX

                                                       

Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries
info@mastthera.com

Investor Relations Contact
ir@mastthera.com

Business Development Contact
busdev@mastthera.com

Careers Contact
hr@mastthera.com

 

                                                                                                 

                                                                                                                                                 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MSTX
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#12435   I think this bottomed in .40's. Wait JDLAXXE 12/18/14 01:46:30 PM
#12434   BIg pharma will buy MSTX wait next year sedrik 12/18/14 09:14:56 AM
#12433   P:T 3 sedrik 12/18/14 09:14:08 AM
#12432   Mast Announces Plans For Development Of Vepoloxamer (MST-188) sedrik 12/18/14 09:13:49 AM
#12431   I believe all the investment has dried up pray 12/15/14 11:36:54 PM
#12430   MSTX news Ecomike 12/10/14 05:43:13 AM
#12429   If you invest money in MAS that you Cicant 12/10/14 01:17:55 AM
#12428   http://www.masttherapeutics.com/investors/news/?releaseid=1996054 Rhodey Red 12/09/14 08:12:06 AM
#12427   It's certainly trading in a tight channel. Rhodey Red 12/09/14 08:03:58 AM
#12426   Doubt this will go by .48 until all pray 12/09/14 12:22:55 AM
#12425   Strong trading action into final hour off of Rhodey Red 12/08/14 03:00:02 PM
#12424   What presantation wos good sedrik 12/08/14 06:25:43 AM
#12423   Mast is presenting tonight 6-8 pm PST.http://finance.yahoo.com/news/mast-therape Rhodey Red 12/07/14 05:56:20 PM
#12422   Not only Move up, but move up big wallstreetbuyer 12/07/14 12:51:31 PM
#12421   MSTX weekly chart might tell you something.. carp1 12/07/14 11:57:44 AM
#12420   Does it have a history of moving up tmeier 12/07/14 10:45:24 AM
#12419   Anything new ? wallstreetbuyer 12/07/14 08:30:33 AM
#12418   Piper Jaffray Audiocast Presentation: http://www.media-server.com/m/p/q6tpwb4g Rhodey Red 12/03/14 11:12:29 AM
#12417   After flipping out at .60 a few months RNsidersbuying 11/25/14 12:21:52 PM
#12416   Its stuck in the bloody .40's now, but JDLAXXE 11/25/14 07:49:12 AM
#12415   11/21/14-9:30a lecorb 11/24/14 09:13:21 AM
#12414   Hard to move above .50 with past offering. pray 11/24/14 08:14:38 AM
#12413   I'm holding for next spike. 1's or more JDLAXXE 11/22/14 09:47:01 PM
#12412   Lecorb would you mind linking the Cowen initiation laker2000 11/21/14 06:17:33 PM
#12411   Two analysts in four days, buy with a lecorb 11/21/14 04:42:54 PM
#12410   CEO Golf Lessons ...... pray 11/21/14 04:28:30 PM
#12409   Nice sell just now....probably the company tapping the TriggerPuller79 11/21/14 10:33:22 AM
#12408   Mast Therapeutics Started at Outperform by Cowen MSTX lecorb 11/21/14 09:55:23 AM
#12407   Yeah baby yeah !!! Go MSTX. The Bread Man 11/21/14 09:06:14 AM
#12406   Interested to see where she opens following last Rhodey Red 11/21/14 08:09:06 AM
#12405   After Hour:11,500 shares buy in ask @.50 16:27:36 lecorb 11/20/14 04:52:51 PM
#12404   Maybe today is the day we go over The Bread Man 11/20/14 10:26:01 AM
#12403   Nice News in with 21.000 shares,good luck and harmsen 11/19/14 02:41:46 PM
#12402   link for Highlander release http://finance.yahoo.com/news/highline-research-advi laker2000 11/19/14 01:32:44 PM
#12401   Mew Coverage, Highlander iniates coverage on Mstx with laker2000 11/19/14 01:32:15 PM
#12400   In level two, upgrade from sell in red, lecorb 11/19/14 08:59:52 AM
#12399   Here's the press release: http://www.marketwatch.com/story/new-data-from-noncli Rhodey Red 11/19/14 08:40:23 AM
#12398   Heart Failure data release via presentation poster for Rhodey Red 11/19/14 08:33:25 AM
#12397   I beleive within a few months MSTX will JDLAXXE 11/18/14 10:51:45 PM
#12396   Well my son is only 18 months so Rhodey Red 11/18/14 09:54:44 PM
#12395   In level two, upgrade from sell in red, lecorb 11/18/14 07:51:53 PM
#12394   When this started going up last December I pray 11/18/14 08:38:55 AM
#12393   Another analyst putting out buy on MSTX. JDLAXXE 11/18/14 12:27:32 AM
#12392   This quarter actually. Waiting on FDA protocol for Rhodey Red 11/17/14 01:28:07 PM
#12391   When will be next major catalyst? Next year? wallstreetbuyer 11/17/14 10:21:57 AM
#12390   Canaccord Genuity Initiates Mast Therapeutics With Buy, $3.00 lecorb 11/17/14 09:12:52 AM
#12389   http://www.masttherapeutics.com/investors/news/?releaseid=1990184 Cicant 11/17/14 09:07:40 AM
#12388   So are we on our way here or The Bread Man 11/13/14 03:46:58 PM
#12387   "whale wisdom" hun? Its your source. JDLAXXE 11/13/14 12:45:59 AM
#12386   Franklin reported position 11,946,100.......Vanguard Gro reported increased pos. laker2000 11/12/14 03:44:21 PM
PostSubject